Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer.

已完结 20 由 Aven 发布于 2026/8/13 15:20:21

DOI:10.1158/1078-0432.CCR-22-0456
作者：Jian Zhang,?Dongmei Ji,?Weina Shen,?Qin Xiao,?Yajia Gu,?Joyce O'Shaughnessy,?Xichun Hu
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：Purpose: ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a

应助信息

1天前

离异带俩喷火龙王

2a2d457096e811f197c234735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2026/8/13 15:20:21 未找到该文献，机器人已退出，请等待人工下载

2026/8/13 15:20:21 Book学术AI机器人收到请求，开始寻找文献

2026/8/13 15:20:21 已向机器人发送请求

1天前

Aven 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierSynergistic effects of Mn, Cr, Fe addition and thermomechanical processing on the strengthening and deformation mechanisms in Al-Mg-Si-Cu alloys with elevated Fe content